Octagon Capital Advisors
Latest statistics and disclosures from Octagon Capital Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are APLS, Cymabay Therapeutics, VRNA, INSM, RCUS, and represent 56.60% of Octagon Capital Advisors's stock portfolio.
- Added to shares of these 10 stocks: GPCR (+$17M), CNTA (+$13M), CYTK (+$9.7M), ALPN (+$9.4M), RAPT (+$7.3M), Gracell Biotechnologies (+$6.0M), VERU, ANAB, NUVB, DYN.
- Started 10 new stock positions in ANAB, PHAT, CYTK, GPCR, RAPT, MIRM, Gracell Biotechnologies, NUVB, ACRS, VERU.
- Reduced shares in these 10 stocks: APLS (-$84M), IMVT (-$31M), Mirati Therapeutics (-$29M), ROIV (-$21M), ETNB (-$19M), AMLX (-$13M), Cymabay Therapeutics (-$11M), BBIO (-$11M), VRDN (-$9.7M), TSHA (-$8.8M).
- Sold out of its positions in AMLX, BNOX, ETNB, HEPA, ITOS, LXRX, Mirati Therapeutics, GLUE, ORIC, PMVP. TSHA, TVTX, VKTX, VIR.
- Octagon Capital Advisors was a net seller of stock by $-202M.
- Octagon Capital Advisors has $625M in assets under management (AUM), dropping by -3.98%.
- Central Index Key (CIK): 0001839435
Tip: Access up to 7 years of quarterly data
Positions held by Octagon Capital Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Octagon Capital Advisors
Octagon Capital Advisors holds 33 positions in its portfolio as reported in the December 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals (APLS) | 26.9 | $168M | -33% | 2.8M | 59.86 |
|
| Cymabay Therapeutics | 10.1 | $63M | -14% | 2.7M | 23.62 |
|
| Verona Pharma Sponsored Ads (VRNA) | 7.5 | $47M | 2.4M | 19.88 |
|
|
| Insmed Com Par $.01 (INSM) | 6.4 | $40M | 1.3M | 30.99 |
|
|
| Arcus Biosciences Incorporated (RCUS) | 5.7 | $36M | -5% | 1.9M | 19.10 |
|
| Bridgebio Pharma (BBIO) | 4.6 | $29M | -27% | 707k | 40.37 |
|
| Celldex Therapeutics Com New (CLDX) | 4.5 | $28M | -6% | 708k | 39.66 |
|
| Roivant Sciences SHS (ROIV) | 4.5 | $28M | -42% | 2.5M | 11.23 |
|
| Alpine Immune Sciences (ALPN) | 3.8 | $24M | +65% | 1.2M | 19.06 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 2.7 | $17M | NEW | 414k | 40.76 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 2.6 | $16M | +333% | 2.1M | 7.96 |
|
| An2 Therapeutics (ANTX) | 2.2 | $14M | -23% | 665k | 20.49 |
|
| Miragen Therapeutics (VRDN) | 2.2 | $14M | -41% | 620k | 21.78 |
|
| Immunovant (IMVT) | 1.8 | $12M | -72% | 273k | 42.13 |
|
| Dyne Therapeutics (DYN) | 1.7 | $11M | +14% | 793k | 13.30 |
|
| Cytokinetics Com New (CYTK) | 1.5 | $9.7M | NEW | 116k | 83.49 |
|
| Annexon (ANNX) | 1.5 | $9.3M | 2.1M | 4.54 |
|
|
| Aerovate Therapeutics (AVTE) | 1.5 | $9.1M | -18% | 404k | 22.63 |
|
| Gossamer Bio (GOSS) | 1.3 | $8.4M | +12% | 9.2M | 0.91 |
|
| Rapt Therapeutics (RAPT) | 1.2 | $7.3M | NEW | 292k | 24.85 |
|
| Glycomimetics (GLYC) | 1.1 | $7.1M | 3.0M | 2.36 |
|
|
| Gracell Biotechnologies Sponsored Ads | 1.0 | $6.0M | NEW | 597k | 10.04 |
|
| Dianthus Therapeutics (DNTH) | 0.9 | $5.8M | +15% | 554k | 10.40 |
|
| Reneo Pharmaceuticals (RPHM) | 0.6 | $3.6M | 2.3M | 1.60 |
|
|
| Jasper Therapeutics | 0.6 | $3.5M | 4.5M | 0.79 |
|
|
| Female Health (VERU) | 0.4 | $2.7M | NEW | 3.8M | 0.72 |
|
| Anaptysbio Inc Common (ANAB) | 0.4 | $2.6M | NEW | 120k | 21.42 |
|
| Inozyme Pharma (INZY) | 0.3 | $1.7M | -69% | 400k | 4.26 |
|
| Nuvation Bio Com Cl A (NUVB) | 0.2 | $1.5M | NEW | 1.0M | 1.51 |
|
| Xilio Therapeutics (XLO) | 0.2 | $982k | -23% | 1.8M | 0.55 |
|
| Mirum Pharmaceuticals (MIRM) | 0.1 | $738k | NEW | 25k | 29.52 |
|
| Phathom Pharmaceuticals (PHAT) | 0.1 | $457k | NEW | 50k | 9.13 |
|
| Aclaris Therapeutics (ACRS) | 0.0 | $105k | NEW | 100k | 1.05 |
|
Past Filings by Octagon Capital Advisors
SEC 13F filings are viewable for Octagon Capital Advisors going back to 2020
- Octagon Capital Advisors 2023 Q4 filed Feb. 14, 2024
- Octagon Capital Advisors 2023 Q3 filed Nov. 14, 2023
- Octagon Capital Advisors 2023 Q2 filed Aug. 14, 2023
- Octagon Capital Advisors 2023 Q1 filed May 15, 2023
- Octagon Capital Advisors 2022 Q4 filed Feb. 14, 2023
- Octagon Capital Advisors 2022 Q3 filed Nov. 14, 2022
- Octagon Capital Advisors 2022 Q2 filed Aug. 15, 2022
- Octagon Capital Advisors 2022 Q1 filed May 16, 2022
- Octagon Capital Advisors 2021 Q4 filed Feb. 14, 2022
- Octagon Capital Advisors 2021 Q3 filed Nov. 15, 2021
- Octagon Capital Advisors 2021 Q2 filed Aug. 16, 2021
- Octagon Capital Advisors 2021 Q1 filed May 17, 2021
- Octagon Capital Advisors 2020 Q4 filed Feb. 16, 2021